Printer Friendly

ANERGEN'S ANERGIX(TM) COMPOUNDS INACTIVATE ALLERGY SPECIFIC T CELLS IN VITRO

 Johns Hopkins Presents Results of Collaborative Study
 at Immunology Conference
 REDWOOD CITY, Calif., May 24 /PRNewswire/ -- Anergen Inc. (NASDAQ: ANRG) today announced that one of its AnergiX(TM) compounds was found to suppress the in vitro activity of T cells which may participate in the initiation of allergy symptoms. These findings, from a collaboration with researchers at The Johns Hopkins Asthma and Allergy Center, were presented today by Thorunn Rafnar, Ph.D., and her associates at the Joint Meeting of the American Association of Immunologists and The Clinical Immunology Society, in Denver.
 The study, conducted at Johns Hopkins, tested in vitro peptide fragments of a highly purified ragweed pollen allergen from a ragweed-allergic patient as a model to examine the molecular nature of T-cell recognition of allergens.
 "The results of this study are consistent with Anergen's therapeutic approach in autoimmune diseases," said Somesh D. Sharma, Ph.D., Anergen's vice president of research and chief scientific officer. "Over the past year we have seen our AnergiX compounds inactivate in vitro specific T cells implicated in multiple sclerosis (MS) and myasthenia gravis (MG). As demonstrated by this collaborative study with Johns Hopkins, we can potentially expand the AnergiX product development program to include allergies," he added.
 Anergen's technology consists of AnergiX compounds comprising purified soluble class II major histocompatibility peptide complexes specific to T cells of interest. The AnergiX compounds target and bind to CD4+ T cells implicated in the progression of disease, triggering anergy or T cell inactivation. Pre-clinical in vitro and animal studies have demonstrated the potential of AnergiX therapies in treating MS, MG and rheumatoid arthritis (RA). The company hopes to file an investigational new drug (IND) filing for one or more of these applications this year.
 Anergen is developing therapies for the treatment of autoimmune diseases using proprietary biopharmaceutical compounds designed to inactivate or anergize only the disease-related T cells in the immune system that are responsible for each disease.
 -0- 5/24/93
 /CONTACT: Joan Shields, investor relations of Anergen, 415-361-8901; or Mark Brand or Kimberly Kraemer of Pondel Parsons & Wilkinson, 310-207-9300, for Anergen/
 (ANRG)


CO: Anergen Inc. ST: California IN: MTC SU:

JB-EH -- LA017 -- 1788 05/24/93 15:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 24, 1993
Words:365
Previous Article:MICHAEL L. LUETKEMEYER NAMED VICE PRESIDENT-CONTROLLER OF HARRIS SEMICONDUCTOR SECTOR
Next Article:CIRCUS CIRCUS ANNOUNCES SITE APPROVAL IN TUNICA, MISS.
Topics:


Related Articles
ANERGEN BEGINS CONSTRUCTION OF PILOT PLANT IN REDWOOD CITY
ANERGEN ISSUED PATENT EXPANDING ITS TECHNOLOGY
ANERGEN COLLABORATES WITH UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY ON THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
ANERGEN REPORTS SECOND QUARTER 1995 RESULTS
ANERGEN NAMES SHERMAN NEW CEO
ANERGEN ENTERS INTO SECOND CORPORATE ALLIANCE
/C O R R E C T I O N -- Anergen/(Correction Notice)
Anergen Receives $2 Million License Fee
Anergen Reports 1996 Financial Results
Anergen Reports First Quarter 1997 Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters